Corcept Therapeutics Incorporated (NASDAQ: CORT) is a Healthcare company (Medical - Pharmaceuticals) with a market capitalization of $7.7B. The Maz Rating grades it against the other companies in its sector.
Corcept Therapeutics Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $70.07, Corcept Therapeutics Incorporated trades at 46.5x trailing earnings, 7.9x sales and 8.9x book value, with an EV/EBITDA of 56.3. Over the last twelve months it generated about $967M of revenue and $165M of net income. It runs a gross margin of 98.5%, an operating margin of 11.5% and a net margin of 16.8%. It shows return on equity of 22.9%, return on invested capital of 12.9% and a free cash flow yield of 2.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 3.00. Over the past 52 weeks the share price ranged from $28.66 to $126.38, with a beta of 0.45.
Corcept Therapeutics Incorporated does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 14 Buy, 9 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Corcept Therapeutics Incorporated (CORT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.94% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.33% / 33% · Receivables / Mkt Cap (36m) 1.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.33% / 33.33% · Receivables / Mkt Cap (24m) 1.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.63% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 38.9% / 33.33% · Receivables / Avg Assets (4Q) 8.03% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 35.9% / 33.33% · (Cash+Recv) / Total Assets 46.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Corcept Therapeutics Incorporated (CORT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Corcept Therapeutics Incorporated is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Corcept Therapeutics Incorporated reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.